Robert’s Journey With EGFR+ Metastatic NSCLC

Opinion
Video

Profiling a 58-year-old retired construction manager with Stage IV EGFR+ NSCLC, discussing his transition from osimertinib to amivantamab plus chemotherapy, managing side effects, and maintaining hope throughout his treatment journey.

Recent Videos
Related Content